Philanthropic Leaders Catalyzing Innovation
Mission
Hoag Innovators is a group of donors with a shared vision for advancing health care innovation at Hoag by leveraging the power of collective giving. The group is defined by its active engagement, discretionary review, and collaborative decision-making on which philanthropic investments will provide the greatest impact.
LETTER FROM THE FOUNDERS
Dear Hoag Innovators,
Thank you for contributing to a standout year for Hoag Innovators! Your support and active engagement continue to fuel our movement and increase our impact.
Hoag Innovators is a community driven by purpose, dedicated to catalyzing health care innovation now and into the future. Marked by our unique approach to philanthropy, our group has demonstrated the ability to attract new members, including many who are first-time donors to Hoag. The Innovators investment portfolio—which consists of 22 projects across the enterprise totaling more than $6.2 million—is branding Hoag as an environment for innovation and enhancing outcomes along with the patient experience. Hoag Innovators has become well-known across the organization, inspiring physicians to think creatively about their specialty’s most pressing challenges. At the same time, our commitment to innovation is adding to Hoag’s capacity to compete for the country’s best and brightest clinicians whose intellectual passions for innovative discovery can be supported.
Still, we know our impact is only just beginning. As we aim to increase funding for innovative clinical projects today and equip Hoag with a sustainable platform for innovation, the Hoag Innovators Advisory Board has set a goal of reaching a total of $50 million raised over the next five years. As of today, Hoag Innovators has raised in excess of $25 million, including $11 million raised for the Hoag Innovators Endowment Fund. Hoag Innovators has thrived because of an engaged, all-in approach to our growth, and we are confident that continuing to promote Hoag Innovators within our networks will help us achieve this lofty goal. We also believe that a significant challenge gift, similar to Mike and Lori Gray’s transformational $5 million challenge gift several years ago in support of the Hoag Innovators Endowment Fund, will accelerate the effort.
We are beyond grateful to be on this journey with you. Thank you for your commitment, your generosity, and your trust in this innovative approach to philanthropy.
Sincerely,
Robert and Kitty Brunswick Founding Hoag Innovators
INFINITE
Giving by Fund
(as of 9/18/24)
Total giving includes multi-year pledges and estate gifts
Hoag Innovators Fund
Hoag Innovators Endowment Fund
Total Funded Projects
$13,948,500
$11,551,364
$6,259,000
Total Raised: $25,499,864
Now in its sixth year of philanthropic investment, Hoag Innovators has funded projects across an increasingly broad range of medical specialties at Hoag, catalyzing innovation throughout the organization like never before. The return is the transformative health care advancements that change the lives of individuals near and far for the better. As Hoag Innovators’ membership and engagement grow, so does its capacity to empower Hoag clinicians to provide cutting-edge care to every patient while furthering Hoag’s reputation as an incubator for innovation and a place where the world’s leading physicians can move medicine forward.
10% Radiology & Imaging
4%
Je rey M. Carlton Heart & Vascular Institute
8% Digestive Health Institute
12% Women’s Health Institute
20% Pickup Family Neurosciences Institute
Hoag Family Cancer Institute
Hoag Family Cancer Institute
Distribution Across Hoag
$150,000
$400,000 $350,000 $293,000
Biocartis Idylla™ Technology Platform for Molecular Diagnostics Testing and Translational Pathology
Prostate Cancer Screening Clinic
Cancer Early Detection Analysis Lab
Total Body Photography: VECTRA WB360 Whole-Body 3D Imaging
$407,000 $405,000
Translational Research Lab
Clinical Pilot of Cognitive Screening in Acute Care Settings: Cognivue
Integrated Center for Pain Relief
Invenio NIO Laser Imaging $250,000 $250,000
MRI-Guided Focused Ultrasound
IMPACT AT THE HIGHEST LEVEL
Dear Hoag Innovators,
One of the best parts of my job is the front row seat it affords me to the work of some of medicine’s most brilliant clinical minds. Hoag has fostered an environment that attracts the best of the best, pioneers who are driving innovation that advances medicine, prevents disease, and transforms health care delivery.
Over the last several years, the support and engagement of Hoag Innovators has galvanized Hoag physicians and their capacity for innovation like never before. Your investment propels them to reach higher and push through the status quo, empowering them from idea to action. You’ve armed them with the most advanced technology and tools so they can lead in their specialties for the benefit of patients in our community and beyond. All of this advances Hoag’s leadership in the health care industry. Truly, Hoag Innovators is a game changer.
I have shared before that the Hoag Innovators brand has become a compelling recruitment tool as Hoag continues to engage the nation’s foremost clinicians. In today’s health care climate, this has never been more important.
I’m grateful for your investment in innovation that has impact. Thank you for your commitment to Hoag and to moving health care forward.
Sincerely,
Robert Braithwaite Hoag President and CEO
PROJECT INVESTMENT UPDATES INNOVATIVE CARE PRACTICE
Prostate Cancer Screening Clinic
The Right Screening for the Right Person at the Right Time
CLINICIAN LEAD:
Jeffrey Bassett, MD, MPH, Benjamin & Carmela Du Endowed Chair in Urologic Oncology
INVESTMENT DATE
Spring 2023
INVESTMENT AMOUNT
$293,000
THE CHALLENGE
According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer. One man in eight will be diagnosed with prostate cancer during his lifetime, and one man in 41 will die from prostate cancer. Historically, prostate cancer screening tools and practices have been limited, but with recent innovations in tests and detection technologies, there is an opportunity to significantly improve the prostate cancer screening process.
THE I NNOVATION
The Prostate Cancer Screening Clinic will bridge the gap between basic screening in a primary care office and advanced screening in a urologic oncology office. A dedicated nurse practitioner will see patients and provide screenings at the clinic using different advanced tools, allowing Hoag’s urologic oncologists to focus on treatment. Working collaboratively with Hoag Medical Group, the Prostate Cancer Screening Clinic will help ensure the right screenings are consistently offered to the right patients.
THE RESULTS
To date, more than 150 patients have been screened for early prostate cancer using a customized urine test optimized by Hoag urologic oncologists Dr. Jeffrey Bassett and Dr. Robert Torrey. These patients are being followed in the Prostate Cancer Screening Clinic, and their clinical information has been entered into a comprehensive database that serves as a crucial tool for analyzing test outcomes and guiding patient surveillance and care. Ongoing data analysis and tracking will determine the needs of the Prostate Cancer Screening Clinic going forward, including increased staffing, expansion to additional physician participation, new partnerships, and additional patient screenings.
Perinatal Nurse Navigator Program
Alleviating Stress and Optimizing Outcomes for Patients with High-Risk Pregnancies
CLINICIAN LEAD:
Kristi Kambestad, MD
INVESTMENT DATE
Fall 2022
INVESTMENT AMOUNT
$300,000
THE CHALLENGE
Hoag is the busiest maternity center in California, with approximately 8,000 deliveries each year. A number of these pregnancies are considered high risk, and about 10% of babies born at Hoag are admitted to the neonatal intensive care unit (NICU). Being diagnosed with a high-risk pregnancy can be overwhelming and difficult to navigate. It often requires care from multiple specialists and a coordinated, comprehensive plan to ensure a healthy pregnancy, delivery, and beyond.
THE INNOVATION
The perinatal nurse navigator provides personalized support, resources, education, and guidance to patients at Hoag with high-risk pregnancies. Through coordinating consults and multidisciplinary conferences with specialists and communicating vital information between providers, the perinatal nurse navigator helps ensure optimal conditions for birth and a comprehensive postnatal care plan for the baby. Thanks to the perinatal nurse navigator, patients faced with the stress and challenges of a highrisk pregnancy can rest assured knowing they will have a personal guide throughout their experience, and both mother and baby will receive the most comprehensive care Hoag can provide. The program elevates Hoag in its provision of service-oriented and patient-centered care on par with larger institutions with this capability.
THE RESULTS
• More than 1,301 patients have been enrolled in the program to date.
• 209 of the expecting mothers enrolled were due to a fetal anomaly (49% were fetal heart conditions).
• More than 60 multidisciplinary care conferences have been held to date. These meetings bring together a team of Hoag physicians across specialties to plan for an individual patient’s high-risk delivery and care plan.
• In cases involving fetal brain and lung abnormalities, the Perinatal Nurse Navigator Program coordinates fetal MRIs with same-day subspecialist consultation.
• In 2023, 355 at-risk mothers were referred to the Hoag Maternal Mental Health Program via the perinatal nurse navigator.
Integrated Center for Pain Relief
A High-Touch, High-Tech Approach to Overcoming Pain
CLINICIAN LEAD:
Charles De Mesa, DO, Chief of Interventional Pain, Physical Medicine & Rehabilitation, Hoag Spine Institute and Director of the Chronic Pain & Neuropathy Program, Pickup Family Neurosciences Institute
INVESTMENT DATE
Fall 2023
INVESTMENT AMOUNT
$400,000
THE CHALLENGE
Pain is the most common reason cited for seeking medical care, yet a person-centered, comprehensive approach to pain management is uncommon. Instead, opioid use is at an all-time high, with the U.S. consuming 80% of the world’s opioid painkillers. Between 2019 and 2021, California’s opioid-related deaths spiked 121%. Emergency departments and hospitals are inundated with individuals who suffer from this crisis with enormous impact on health resources. It’s time for a better way to care for patients suffering from chronic pain.
THE INNOVATION
With a comprehensive, holistic approach that includes interventional and minimally invasive surgical innovations, Hoag’s Integrated Center for Pain Relief will set a new standard for pain management excellence in Orange County. In addition to highly skilled, double and triple board-certified pain physicians representing multiple specialties, streamlined, three-suite fluoroscopy operating rooms will enhance the patient experience and outcomes. Hoag’s Integrated Center for Pain Relief will touch inpatients and outpatients in all specialties at Hoag and will provide pain relief options they never knew were possible.
THE RESULTS
The investment from Hoag Innovators supported the purchase of two Fluoroscopy C-Arm imaging machines, one of which has already been implemented. The other will be operational in 2025 as Hoag prepares to open its new Pain Procedure Suite. The new C-arm allows clinicians to identify the underlying source of pain and then personalize treatment plans accordingly. The C-arm also significantly enhances visualization so that needles are more accurately placed when physicians are delivering steroids and other pain relief medications. As of July 2024, the team has performed more than 588 pain management procedures, and patient volumes have increased steadily every month since the first fluoroscopy C-arm imaging machine was implemented.
Dr. De Mesa’s expertise and compassion brought my husband immense relief after eight months of debilitating pain. The use of the fluoro machine to determine where the inflammation was before injecting him was quite simply brilliant. Dr. De Mesa and his nurse Natalie Davin listened to us, did not rush us through appointments, and took the time to determine what the best path forward would be for my husband. Dr. De Mesa’s skill and patience made a profound difference in his and our lives.”
Hoag Grateful Patient
I absolutely love that fluoro machine! I know that sounds dramatic, but both times it was used for Dr. De Mesa to give me the injection, I felt immediate results. Which, as a patient, tells me it’s working extremely well. This last injection and the use of the fluoro machine–I was in quite a bit of discomfort, and within three to four hours of receiving the injection, I felt much better. By the next morning, I was a new man. What a difference. For me, it’s helped me enjoy life more in a big way. Thank you to Dr. De Mesa and Natalie and the team!”
Hoag Grateful Patient
Marfan Syndrome & Related Conditions Program
Expert Care Locally for Patients with Rare Disease
CLINICIAN LEAD:
David Liang, MD, PhD, Program Director, Marfan Syndrome & Related Conditions Program
INVESTMENT DATE
Spring 2019
INVESTMENT AMOUNT
$250,000
THE CHALLENGE
Marfan syndrome and related conditions are rare and life-threatening genetic disorders that put patients at risk for aortic disease and dissection. Few programs exist in the U.S., so many patients must travel for expert care.
THE INNOVATION
World-renowned cardiologist Dr. David Liang, who was recruited from Stanford thanks in part to the investment provided by Hoag Innovators, leads Hoag’s multidisciplinary team of experts at Hoag’s comprehensive Marfan Syndrome & Related Conditions Program. The only comprehensive Marfan syndrome program in Southern California, it’s also the only one at a community hospital in the United States.
THE RESULTS
• More than 1,864 patients have been seen in the Marfan Syndrome & Related Conditions Program clinic since it opened. In 2023, 674 patients were seen.
• Hoag’s Marfan Program team has completed 781 genetic evaluations since the program launched, including 268 evaluations in 2023.
• There are currently 99 families being monitored in the program.
• The Marfan team has confirmed 126 connective tissue disease diagnoses since the program opened, including 44 in 2023.
• As of March 2024, 242 patients have requested to transfer their care from Stanford to Hoag.
It is terrifying and lonely to live with a rare and lifethreatening disease that most people have never heard of. Meeting Meg, the Marfan Syndrome & Related Conditions Program nurse navigator, was the first time I felt that my family and I weren’t so alone in our vEDS journey. As a physician assistant working in hematology oncology, I understand what it takes to comfort a patient in their darkest times and provide excellent care. Dr. Liang and his team surpassed all of my expectations. I have finally found my home. Because of your donations, Hoag is now at the forefront of Marfan syndrome and related conditions research and education. I now have the opportunity to receive a life-saving drug here at Hoag through a clinical trial. What was once an impossibility is now a reality. Thank you, Hoag Innovators.”
Kaitlin, Grateful Patient
Augmented Reality for Interventional Radiology Program
The Future of UltrasoundGuided Procedures for Patients with Rare Disease
CLINICIAN LEAD:
Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology, Sun Family Campus, Hoag Irvine
INVESTMENT DATE
Spring 2024
INVESTMENT AMOUNT
$350,000
THE CHALLENGE
Ultrasound-guided procedures are common in the field of interventional radiology but have seen little advancement in decades. There are numerous challenges with ultrasound-guided procedures, including image quality, the ability to visualize lesions and internal organs, and ergonomics of the equipment. Thousands of ultrasound-guided procedures are performed every year by Hoag’s interventional radiology team, and an increasing number of patients require these procedures. Today’s physicians and patients are requesting smaller, harder to access, and more technically difficult targets for biopsy and minimally invasive intervention.
THE INNOVATION
Augmented reality (AR) has the power to revolutionize interventional radiology and is in its infancy of what’s possible. The MediView AR is comprised of a powerful computer and imaging headset that registers large amounts of complex patient imaging data into a three-dimensional space allowing the operator to clearly visualize the patient’s internal organs, disease pathology, and interventional tools rendered in real time and in an ergonomically proficient manner. As a result, operators can perform ultrasound-guided procedures quicker, easier, safer, and more effectively than ever before.
THE RESULTS
Hoag is in the process of implementing MediView XR90 in the radiology procedures unit of the Sun Family Campus in Irvine, which will be followed by training Hoag physicians and clinical staff. Once launched, Hoag will become the first non-academic hospital in the world and first hospital on the West Coast to perform interventional radiology procedures using the three-dimensional, holographic, augmented reality visualization and navigation ultrasound system. This will open new avenues for research inquiry, education, and industry partnerships while positioning Hoag as a pioneer in an unprecedented new age of AR-driven intervention.
Comprehensive Esophageal Diagnostic and Interventional Program
Earlier Diagnosis and Faster Relief for Patients with Esophageal Disorders
CLINICIAN LEAD:
Katie
Blevins, MD, PhD
INVESTMENT DATE
Spring 2024
INVESTMENT AMOUNT
$250,000
THE CHALLENGE
One in four adults in the U.S. suffers from gastroesophageal reflux disease (GERD). In addition to a host of symptoms that impact quality of life, GERD can lead to serious health complications, including esophageal cancer, if left untreated. Esophageal disease is complex and requires a wide spectrum of advanced technology to help quickly diagnose the issue, as well as a comprehensive team to provide expert medical management.
THE INNOVATION
A transformational trio of technology will complement the expertise of Hoag’s world-class clinical team, accelerate early and accurate diagnoses for patients suffering from esophageal disorders, and further differentiate Hoag’s Digestive Health Institute. The mucosal integrity testing technology, or MiVu, instantly detects or rules out GERD instead of waiting a week (or longer) for traditional results with 95% accuracy compared to traditional methods at 64%. EndoFLIP™ provides efficient, dynamic measurements of the esophagus and tests for multiple esophageal conditions. With alpHaONE wireless pH capsule reflux monitoring, reflux can be tracked in patients over several days and vastly improves on the previous experience.
THE RESULTS
The MiVu, EndoFLIP™, and alpHaONE wireless pH capsule reflux monitoring system have been ordered and will be operational at Hoag by early 2025. Hoag will be the only health care system in Orange County to offer this comprehensive diagnostic platform, enhancing Hoag’s status as a leader and enabling more research and innovation that will advance care.
“We’re so grateful to have the support of Innovators to be able to offer the most cutting-edge technology in esophageal care. I recently saw a patient that was elated to hear Hoag is getting a new, nickel-free, convenient way to diagnose her GERD. She had a terrible time with this test previously due to sensitivity, and her anxiety dropped visibly when I told her about our new technology. Thank you for helping us be able to provide these options to our patients!”
– Dr. Katie Blevins
Using Sound Waves to Cure the Brain
Transforming Brain Tumor Treatment
CLINICIAN LEAD:
Robert Louis, MD, FAANS, Empower360 Endowed Chair in Skull Base and Minimally Invasive Neurosurgery, Chief, Division of Neurosurgery, Pickup Family Neurosciences Institute
INVESTMENT DATE
Spring 2024
INVESTMENT AMOUNT
$500,000
THE CHALLENGE
Despite advances in nearly all other cancer types, treatment for brain cancer along with survival rates have seen little improvement in the last 30 years. Only 12% of those diagnosed with a malignant brain tumor survive longer than five years. Treatment options are limited by the fact that 99% of medications cannot access the brain due to the blood-brain barrier, the same layer that protects the brain from harmful substances.
THE INNOVATION
MRI-guided focused ultrasound (MRgFUS) has been shown to be the most promising technique that can temporarily open the blood-brain barrier and the blood tumor barrier in all areas of the brain. Using sound waves to enter the brain non-invasively, MRgFUS significantly improves the transit of chemotherapeutic agents into the brain, alters the tumor microenvironment to allow for migration of cancer-killing immune cells, and can be safely combined with existing treatments and experimental therapies for patients with brain tumors. The device is currently FDAapproved for medication-refractory essential tremor and Parkinson’s disease-associated tremors and can serve hundreds of Hoag patients yearly with these conditions in addition to giving new hope to patients with brain tumors. MRgFUS has potential future applications in other neurological diseases, including addiction, depression, and Alzheimer’s disease.
THE RESULTS
Hoag Innovators’ investment is supporting the acquisition of the MRgFUS equipment, which will be operational within the Pickup Family Neurosciences Institute and Hoag Family Cancer Institute in early 2025. The Hoag team will also collaborate with the manufacturer of MRgFUS on clinical trials to maximize and advance the technology.
PeriGen Vigilance
Improving Newborn Outcomes Using Artificial Intelligence
CLINICIAN LEADS:
Lisa Karamardian, MD, FACOG, Jeffrey M. Carlton Endowed Chair in Women’s Health, in honor of Dr. Anne M. Kent and David Lagrew, MD, Chief of Maternal Fetal Medicine
INVESTMENT DATE
Fall 2023
INVESTMENT AMOUNT
$299,000
THE CHALLENGE
Nationally ranked in Maternity Care by U.S. News & World Report, Hoag delivers more than 8,000 babies every year. While the hope is that every delivery will be routine, unforeseen issues can arise that require immediate attention to protect the health of mom and baby. Labor and delivery units worldwide face challenges in timely and accurate diagnoses, monitoring, and intervention. Regardless of the health care professional’s skill level, manual processes can lead to errors, delays, and suboptimal resource allocation.
THE INNOVATION
PeriGen Vigilance uses artificial intelligence and other analytical techniques to continuously analyze maternal vital signs, fetal heart rate, uterine contractions, and labor progression. The unique technology provides an automated early warning system and clinical decision support tool for obstetrics, which allows clinicians to quickly see if maternal or fetal conditions are worsening to be able to act right away. PeriGen removes the subjectivity in interpreting fetal well-being by nurses and obstetricians, which helps ensure the best outcomes and experience for the thousands of babies born at Hoag every year and their moms.
THE RESULTS
PeriGen Vigilance was implemented in Hoag’s Labor and Delivery Unit in July of 2024. With physician training complete, the technology is now in operation.
Hoag
Translational
Research Lab
Translating Scientific Discovery to Cancer Care Faster
CLINICIAN LEAD:
Sourat Darabi, PhD, MS, Director of Precision Oncology, Hoag Center for Applied Genomic Technologies
INVESTMENT DATE
Fall 2023
INVESTMENT AMOUNT
$405,000
THE CHALLENGE
The pace of scientific discovery in cancer is more rapid than ever, particularly in the realm of precision medicine and applied genomics, which takes a personalized, targeted approach to cancer treatment and surveillance. As new tests examining RNA sequencing, DNA methylation, long-read DNA, proteomics, single-cell sequencing, immune profiling, flow cytometry, and myriad techniques emerge, it is a challenge to decide if and when to integrate them into bestpractice precision medicine programs to improve patient outcomes.
THE INNOVAT ION
Translational research is the bridge from basic research discoveries to novel improvements in patient care and typically utilizes specimens like blood or tumor tissue that must be acquired from patients. The Hoag Translational Research Lab will allow Hoag’s Precision Medicine Program to explore new technologies at an accelerated pace and curate them for Hoag physicians to provide emerging treatment protocols to their patients. Most community hospitals lack the resources or expertise to operate a translational research lab, while many academic centers with translational research labs do not have direct access to primary patient samples. Hoag has both the expertise and availability of clinical samples to launch a comprehensive hub of experimental design, knowledge creation, and information exchange that will improve clinical outcomes for patients with cancer and further distinguish the Hoag Family Cancer Institute.
THE RESULTS
Hoag Innovators’ investment enabled the acquisition of ZetaView® QUATT, a technological instrument equipped with four lasers at different wavelengths and an ultra-powered camera for the analysis of nanoparticles. The Hoag precision medicine team is using the ZetaView® to study a biomarker called tetraspanins on exosomes isolated from plasma donated by patients with cancer to derive insights that have the potential to lead to breakthrough diagnostics and therapeutics. The Hoag Translational Research Lab also houses the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) laser, a tool used by Hoag’s precision medicine team to identify markers of cancer recurrence or growth, funded by Hoag Innovators as part of the Cancer Early Detection Analysis Lab in the spring of 2021. Additional technologies that will aid in hereditary cancer early detection and other biomarker discovery will be purchased soon. As the Hoag Translational Research Lab continues to develop, there will be opportunities for collaboration with different Hoag physician-scientists as well as external collaborators.
Mobile C-Arm Cios Spin Imaging Equipment
Improving Outcomes and
Comfort
for Patients with Pulmonary Disorders
CLINICIAN LEAD:
Javier Longoria, MD
INVESTMENT DATE
Spring 2023
INVESTMENT AMOUNT
$407,000
THE CHALLENGE
Traditional diagnostic and therapeutic options for patients with pulmonary disorders, including lung cancer, are invasive and uncomfortable with a 25% rate of medical complications.
T HE I NNOVATION
This real-time 3D imaging technology will be utilized during robotic assisted bronchoscopies for patients with lung cancer and other pulmonary disorders. With the mobile C-arm Cios Spin system, surgeons receive 3D confirmation of positioning while a robotic bronchoscope is advanced through the airway, which eliminates the need for incision and provides a 90% or higher accuracy rate with complication rates below 2%. It is also significantly more comfortable for the patient, leads to fewer follow-up procedures, and allows for diagnosis and treatment of a lesion in the same procedure.
THE RESULTS
• The 3D mobile C-arm has been used in more than 284 procedures since it was installed at Hoag in September 2023.
• The technology is allowing pulmonologists and thoracic surgeons to do things they couldn’t conceive of prior to the 3D mobile C-arm, including taking much smaller and more precise segments of tissue.
• Using the 3D mobile C-arm allows Hoag physicians to detect lung cancer sooner and begin treatment more quickly.
• The 3D mobile C-arm is also being used for bedside bronchoscopy procedures. This is done under twilight sedation with the physician, nurse, and respiratory therapist collaborating at the patient’s bedside.
• The Hoag team will soon begin using the 3D mobile C-arm in ablations for thoracic malignancies.
“The 3D mobile C-arm has emerged as a game changer in the field of surgical navigation, revolutionizing the way complex lung procedures are executed and significantly improving patient outcomes. Our team is incredibly grateful for the ability to work with the leading technology in patient care.”
– Dr. Javier Longoria
Invenio NIO Laser Imaging System
Increasing Efficiency and Accuracy of GI Biopsy Procedures
CLINICIAN LEAD:
Phuong Nguyen, MD, Medical Director, Advanced Endoscopy Center
INVESTMENT DATE
Fall 2022
INVESTMENT AMOUNT
$250,000
THE CHALLENGE
Hoag performs over 4,000 tissue biopsies per year for diagnostic and treatment planning. With the traditional method, frozen tissue samples take 30-45 minutes to transport to the lab and process, and this procedure may need to be repeated multiple times before the sample contains diagnostic cells. Further, the frozen tissue samples can contain artifacts, which decreases the accuracy of the sample.
THE INN OVATION
The NIO Laser Imaging System creates high-digital microscopic images of unprocessed tissue in under three minutes with a considerable degree of accuracy. Support from Hoag Innovators in 2019 enabled Hoag to be an early adopter of the NIO Laser Imaging System for neurosurgery. Use of the NIO Laser Imaging System is a novel approach for GI biopsies that leads to overall faster GI procedures by expediting diagnosis and decreasing anesthesia time for the patient. The increased accuracy spares healthy tissue, improves efficiency, and decreases procedure costs. For a procedure that would take 160 minutes through surgery, NIO can be completed in eight minutes.
THE RESULTS
• More than 83 GI cases have been completed with NIO in Hoag’s GI Lab to date, including 68 pancreas cases, two liver cases, and 13 multi-organ cases.
• Hoag has expanded NIO into interventional pulmonology with more than 138 lung cases completed to date.
• Hoag was the first site in the nation to scan a highly aggressive fungal with NIO which provided quick information to the interventional pulmonology team for proper treatment. A case report was submitted for publication in a peer-reviewed journal.
• The system has revolutionized intraoperative diagnosis of pancreatic cancer at Hoag using laser imaging and AI. Hoag was the first in the world to present the use of NIO for endoscopic ultrasound (EUS)-guided biopsy of pancreatic masses at the Digestive Disease Week exhibit in Chicago, IL. The pilot study completed at Hoag is being submitted for publication.
• Hoag is participating in a large multi-center trial for AI validation with the NIO in pulmonology.
• Grant submissions for a large multi-center study that will include Hoag for AI validation with the NIO in pancreas have been submitted.
The Innovators have helped us improve patient care at Hoag through cutting-edge technology with the NIO Laser Imaging System. With NIO, patients can leave the hospital with a preliminary, expedited diagnosis and do not have to return for a second biopsy, which reduces risks associated with anesthesia. The technology ensures our doctors have the immediately available information needed to deliver the best possible care.”
Dr. Phuong Nguyen
Total Body Photography: VECTRA WB360 Whole-Body 3D Imaging
Enhancing Skin Cancer
Early Detection
CLINICIAN LEAD:
Steven Wang, MD, Medical Director, Dermatologic Oncology
INVESTMENT DATE
Spring 2022
INVESTMENT AMOUNT
$400,000
THE CHALLENGE
Melanoma is the deadliest form of skin cancer, and Southern California has one of the highest incidences of the disease in the world. Implementing better methods of early detection, especially for those at increased risk of developing melanoma and other skin cancers, can save lives.
TH E INNOVATIO N
The VECTRA WB360 whole-body 3D imaging system uses 46 cameras that spontaneously fire to capture 3D total body images, allowing patients to have all their moles and lesions mapped out in less than two seconds. The technology allows clinicians to track changing lesions, identify those of concern, and detect melanoma and other skin cancers sooner than with traditional detection methods. The technology not only reduces the number of unnecessary biopsies, it also fundamentally changes the way dermatologists deliver care to high-risk patients with a history of skin cancer. Thanks to the support of Hoag Innovators, Hoag is the first institution in California to adopt VECTRA WB360 whole-body 3D imaging, joining the ranks of Memorial Sloan Kettering Cancer Center and Johns Hopkins Medicine.
THE RESULTS
• More than 136 patients have been scanned on the VECTRA WB360 since it was installed in May of 2023.
• Funds from Hoag Innovators’ investment also supported the acquisition of five D200 handheld digital dermoscopes. The smaller scanning devices are used on every patient in Hoag’s Melanoma & Skin Cancer Program to detect lesions.
• In the last year, the VECTRA WB360 helped the Hoag team detect 12 melanomas and 240 basal and squamous cell carcinomas.
• Patients see the difference the VECTRA WB360 makes in their skin surveillance and feel confident that nothing is missed.
My family has been battling melanoma for decades, first, with my mother’s diagnosis and now mine. We have been very fortunate to receive wonderful care from skilled clinicians throughout our diagnoses and years of treatment, but that does not mean that the monitoring of our skin has been straightforward or easy. That monitoring seems to bring on much second guessing and an overall lack of certainty. The VECTRA has changed much of that. The completely painless photographic scan took less than a minute and provided what I think of as a 'photographic memory' for my doctor, giving us a much-improved ability to track potentially cancerous changes in my skin and act on them quickly. In short, it is a remarkable and comforting advancement that I feel very fortunate to be able to access.”
Terry, Grateful Patient
Clinical Pilot of Cognitive Screening in Acute Care Settings:
Cognivue
Setting the Standard for Cognitive Health Assessments
CLINICIAN LEAD:
Lauren Bennett, PhD, ABPP-CN, Director of Neuropsychology; Director of Psychology Externship Training; Clinical Supervisor, Orange County Vital Brain, Pickup Family Neurosciences Institute
INVESTMENT DATE
Spring 2022
INVESTMENT AMOUNT
$200,000
THE CHALLENGE
There is no current standard of care for assessing cognitive health within the U.S. In addition to increased age, a number of medical conditions, diseases, and health episodes can cause cognitive decline. Identifying changes in cognitive function at the earliest possible time will help ensure appropriate triage and diagnosis, ultimately leading the patient to the right treatment plan sooner.
THE INNOVATION
Cognivue is the first FDA-cleared technology for self-administered computerized cognitive assessment. Test results are provided for six cognitive domains, including visual perception, attention, language, memory, delayed recall, and abstraction. With Hoag Innovators’ funding, Hoag will be the first in Southern California to implement Cognivue to conduct routine cognitive function screenings across a broad range of neurological disorders.
THE RESULTS
• More than 900 patients have completed neurological assessments with Cognivue to date.
• Cognivue screening has been deployed across multiple inpatient and outpatient settings, including the Epilepsy Monitoring Unit, Outpatient Neuropsychological Assessment Clinic, Hoag Medical Group (primary care), and Neurology Specialty Outpatient Clinic, with a dedicated full-time staff member utilizing the device and assisting with triage based on results.
• Use of the Cognivue in Hoag Medical Group has increased access to timely diagnosis and intervention for primary care patients.
• Clinical research with Cognivue is ongoing. The Hoag team gave two presentations at the International Neuropsychological Society’s February 2024 conference in New York City featuring data from Hoag’s Cognivue assessments.
“Having the Cognivue tool available has allowed our providers to detect the earliest signs of cognitive change to expedite diagnosis and treatment like never before.”
– Dr. Lauren Bennett
Biocartis
Idylla™ Technology Platform for Molecular Diagnostics Testing and Translational Pathology
Increasing the Speed of Cancer Diagnosis Early Detection
CLINICIAN LEAD:
David Braxton, MD, Medical Director, Molecular Pathology
INVESTMENT DATE
Fall 2021
INVESTMENT AMOUNT
$150,000
THE CHALLENGE
Every patient’s cancer is unique. Through the molecular testing of tumors, gene abnormalities or mutations causing a patient’s cancer can be identified, which is the key to unlocking the treatment that will be most effective. Performing molecular testing in-house instead of using an outside laboratory can save precious time when it comes to diagnosis and initiation of a targeted treatment plan while decreasing cost.
THE INNOVATION
The Biocartis Idylla™ Technology Platform is a fully automated, real-time, in-house molecular testing system for cancer patients to guide targeted, personalized treatment decisions.
THE RESULTS
• The Biocartis Idylla™ Technology Platform is being used to test to the tumor samples of Hoag patients with advanced stage cancers of the colon, liver, lymph node, melanoma, stomach, thyroid, and brain for the BRAF V600 mutation. Those who have tested positive are candidates for targeted therapy.
• With Idylla™, test results are available in less than 24 hours, whereas tests performed in commercial labs take 10-14 days for results. The Idylla™ is used for inpatients at Hoag who are very ill.
• The Hoag molecular pathology team is currently working on launching the next Idylla™ test for EGFR gene mutations for lung cancer and KRAS mutations for many types of cancers.
Center for Artificial Intelligence and Advanced Imaging - AI2
Harnessing the Power of AI to Improve Imaging
CLINICIAN LEAD:
Scott Williams, MD, Chief of Service and Medical Director, Department of Radiology, Hoag Hospital Newport Beach
INVESTMENT DATE
Spring 2021
INVESTMENT AMOUNT
$250,000
THE CHALLENGE
Advances in CT technology have significantly increased the amount of data and information presented to the radiologist. Imaging studies that once consisted of 50-60 slices through a region of the body now comprise hundreds or even thousands of images. These data-rich exams must be carefully but expeditiously evaluated to diagnose subtle abnormalities that may be life threatening.
THE INNOVATION
With the rise of artificial intelligence applications, medical imaging companies have concentrated on developing algorithms to assist in the detection and timely reporting of critical abnormalities on CT scans. The Hoag Innovators’ investment will help Hoag Radiology leverage the power of artificial intelligence in medical imaging.
THE RESULTS
Hoag Radiology has implemented a robust AI platform called Aidoc, which has enhanced Hoag radiologists’ ability to efficiently identify thousands of life-threatening conditions in inpatients, outpatients, and ER patients. Additionally, AI-driven algorithms have assisted in expediting the interpretation of examinations and most importantly have allowed Hoag Radiology to notify care teams instantaneously to rapidly implement life-saving treatment. Hoag administration has recognized the benefit of AI for the Hoag community and has committed to funding the technology going forward. Hoag will soon be implementing Aidoc enterprise-wide, which will accelerate Hoag’s advancement as an industry leader in health care AI. Since implementation in July of 2022:
• 231,252 cases have been analyzed with Aidoc.
• 9,254 cases were flagged with positive findings.
• Incidental cases are prioritized up to 67% faster.
• 90 workstations at Hoag are running Aidoc.
• $173,000 in additional annual revenue from hospital admissions realized due to enhanced detection of various conditions.
“AI has revolutionized clinical radiology at Hoag. Through our robust partnership with Aidoc and the generosity of Hoag Innovators, Hoag is at the cutting edge of diagnostic radiology care.”
– Dr. Scott Williams
Cancer Early Detection Analysis Lab
Identifying Cancer
Recurrence Sooner
CLINICIAN LEAD:
Michael Demeure, MD, MBA, FACS, FACE, Otis Healy Family Endowed Chair in Applied Genomics, Program Director, Hoag Precision Medicine
INVESTMENT DATE
Spring 2021
INVESTMENT AMOUNT
$350,000
THE CHALLENGE
Using innovative applied genomics technology, physicians can develop a personalized, non-invasive approach to each cancer survivor’s post-treatment surveillance. Cancer recurrence is a significant risk for many cancer survivors, and this new technology can help physicians detect cancer recurrence at the earliest possible stage, offering the best chance at successful treatment. Providing physicians with timely data can also indicate when conventional treatments are not working, allowing for immediate treatment revisions and alterations.
THE INNOVATION
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) provides analysis of the protein content of exosomes—small vesicles produced by cancer cells that contain DNA, RNA, microRNA, lipids, and proteins. Hoag’s precision medicine team will use this new technology in a clinical research study to develop personalized protein signatures to create biomarkers by analyzing patient blood and/or urine samples. Samples will be obtained prior to, during, and after cancer surgery and treatment, providing a longitudinal set over the course of their disease. These real-time samples will identify protein increases or spikes in patients, indicating cancer recurrence or growth sooner than traditional methods.
THE RESULTS
• The Hoag precision medicine team has acquired instruments for exosome extraction from plasma samples, quality assurance of extracted exosomes, and the MALDI-TOF MS laser for proteomic analysis, all of which is housed in the Hoag Translational Research Lab, funded by Hoag Innovators.
• The recently hired lab scientist and precision medicine team have spent time finetuning methods and instrument settings. There is now a reliable and reproducible analysis pipeline, and the team is currently analyzing patient samples.
• To date, 218 patients have been screened and 111 have been enrolled in the study who will donate blood samples before and after cancer surgery for protein analysis.
• Early results have uncovered a possible biomarker for thyroid cancer that warrants continued investigation.
• The team applied for and was recently awarded a $500,000 grant from the Beckman Foundation to further this work.
Invenio NIO Laser Imaging
Reducing Length of Surgery for Patients
CLINICIAN LEAD:
Robert Louis, MD, FAANS, Empower360 Endowed Chair in Skull Base and Minimally Invasive Neurosurgery; Chief of Neurosurgery, Pickup Family Neurosciences Institute
INVESTMENT DATE
Fall 2019
INVESTMENT AMOUNT
$125,000
THE CHALLENGE
Pathology examination of specimens removed during neurosurgery can take up to 30 minutes before surgery can continue. Adopting novel pathology and imaging technology can decrease time spent in surgery by minimizing the wait for pathology analysis of the patient’s specimens.
THE INNOVATION
The NIO Pathology and Slide Imaging System allows examination of specimens from multiple sites in the patient in real time, rather than waiting 30 minutes or more for each sample to be analyzed in the pathology lab. The high quality of the Invenio images allow neurosurgeons to make a more accurate diagnosis in some cases. To maximize the technology even further, Hoag’s team established connectivity to Ambra, a cloud-based image management system, for web stream of images directly from the OR to the lab, enabling further streamlining and more rapid diagnosis. The Hoag team also recently activated the system’s artificial intelligence feature, which sends an AI diagnosis via text message to the surgeon within five minutes.
THE RESULTS
• As of June 2024, a total of 576 neurosurgery cases have been completed with the Invenio NIO Laser Imaging System.
• Average time savings compared with conventional frozen section is 25 minutes.
• Thanks to Hoag Innovators’ investment, Hoag was one of the first institutions in the country to use Invenio. Since then, it has been implemented at many top-tier medical institutions, including academic medical centers which are now publishing results demonstrating its effectiveness.
LEAF Device System Implementation in Critical Care Units
Preventing Pressure Injuries to Critical Care Patients
CLINICIAN LEAD:
Elmira Burke, MSN, RN, CPPS, Chief Patient Safety Officer
INVESTMENT DATE
Spring 2019
INVESTMENT AMOUNT
$125,000
THE CHALLENGE
Patients endure painful hospital-acquired pressure injuries (HAPIs)— injuries to the skin or underlying tissue from prolonged pressure—when their mobility is limited or when they are unable to change positions in bed. HAPIs can complicate a patient’s recovery, but they can be prevented through timely patient repositioning.
THE I NNOVATION
The LEAF Device System is an innovative monitoring system that uses a sensor adhered to the patient’s chest to detect their position and movement. The care provider can remotely monitor and reposition the patient at exactly the right time to prevent injuries from prolonged pressure. The LEAF Device System is currently being used in Hoag’s critical care units (CCUs).
THE RESULTS
• 93% turn protocol adherence (turn protocol adherence > 85% has been shown to significantly reduce hospital-acquired pressure injuries. Literature shows hospitals without LEAF monitoring have a baseline turn protocol adherence between 38% to 52%).
• LEAF has helped Hoag achieve greater than 80% reduction in hospitalacquired pressure injuries in critical care units and elimination of reportable hospital-acquired pressure injuries.
• With the success of the LEAF device on high-risk patients in Hoag’s CCUs, the Hoag patient safety team will be piloting the LEAF device on a noncritical care unit at both Hoag Newport Beach and Hoag Irvine. The pilot is scheduled to go live in August 2024.
PROJECT INVESTMENT UPDATES COMPLETED PROJECTS
Xenex® UV GermZapping Robots
Exceeding Infection Prevention Standards
CLINICIAN LEAD:
Philip Robinson, MD, Medical Director, Infection Prevention and Hospital Epidemiology
INVESTMENT DATE
Spring 2020
INVESTMENT AMOUNT
$180,000
FINAL REPORT PRESENTED:
Spring 2022
Hoag Pacify App
Supporting Healthy Moms and Babies
CLINICIAN LEAD:
Allyson Brooks, MD, FACOG, Ginny Ueberroth Executive Medical Director Endowed Chair, Women’s Health Institute
INVESTMENT DATE
Fall 2019
INVESTMENT AMOUNT
$175,000
FINAL REPORT PRESENTED:
Fall 2022
HOAG INNOVATORS | IMPACT REPORT
THE RESULTS
Hoag’s commitment to infection prevention and patient safety drives the organization’s continuous search for innovative ways to enhance the hospital’s cleaning and disinfecting processes. Using UV technology to disinfect without causing damage to hospital surfaces, the Xenex® UV Germ-Zapping Robots provide an extra layer of protection against the bacteria and germs that can lead to health careassociated infections and surgical site infections.
The robots are deployed in operating rooms and other inpatient areas at Hoag Hospital Newport Beach and Hoag Irvine daily after a rigorous manual cleaning, contributing to a sustained reduction in Hoag’s surgical site infection rate.
THE RESULTS
During the early days of a newborn baby’s life, parents need fast answers and resources they can trust. The Hoag Pacify app facilitated virtual, 24/7, on-demand access to valuable postpartum resources, including lactation consultants, nutritionists, midwives, and social workers.
Available in both English and Spanish, the app served approximately 3,500 moms who delivered at Hoag with critical support when they needed it most. Hoag Innovators’ support for Pacify enabled Hoag to demonstrate proof of concept, functionality, and market interest for development of a Hoag-built app—Nona—that is now available to patients and offers expanded support for both pregnant women and new moms.
Transitional Care Pilot Program
Preventing Hospital Readmissions
CLINICIAN LEAD:
Grace Lozinski, MD
INVESTMENT DATE
Fall 2019
INVESTMENT AMOUNT
$100,000
FINAL REPORT PRESENTED:
Spring 2023
NK Cell Therapy Program
Revolutionizing Pancreatic Cancer Treatment
CLINICIAN LEAD:
Tara Seery, MD, Medical Director, Hepatobiliary Cancer and Co-Director of Cellular Therapy
INVESTMENT DATE
Fall 2020
INVESTMENT AMOUNT
$500,000
FINAL REPORT PRESENTED:
Fall 2024
THE RESULTS
Patients with multiple and complex medical conditions face myriad obstacles in their recovery upon discharge from the inpatient setting, which can lead to emergency department visits and hospital readmissions. Hoag Innovators enabled the launch of the one-year Transitional Care Pilot Program to develop an effective way to support these patients. Participants received post-discharge home health care and resource coordination.
The pilot provided a deeper understanding of what is required to provide effective post-discharge care coordination for medically complex patients and served as a proof of concept for successful delivery of acute services in the home setting. This knowledge helped establish the Hoag at Home Program, which is the second largest home health care provider in Orange County as of 2023.
THE RESULTS
Considered one of the deadliest cancers, pancreatic cancer is one of the few cancers for which there has not been substantial treatment advancements. Currently, only 9% of individuals diagnosed survive for five years or longer. Thanks to Hoag Innovators, the Hoag Family Cancer Institute was one of only two sites in the country to offer the most advanced immunotherapy clinical trial available for locally advanced and metastatic pancreatic cancer.
In partnership with ImmunityBio, the trial used innovative NK (natural killer) cells, which are manipulated to recognize and target cancer cells. When injected into the patient, the NK cells activate the patient’s immune system to create antibodies that fight cancer in combination with chemotherapy. A total of 54 patients were enrolled in the trial at Hoag, many of whom traveled from out of state or even out of the country. The findings informed a new protocol recently written by Dr. Seery for a subsequent clinical trial studying the use of NK cells in combination with the chemotherapy agent NALIRIFOX as the first line of care for advanced pancreatic cancer, which could change the standard of care for pancreatic cancer.
“Our NK cell therapy trial put Hoag on the map for pancreatic cancer, and we definitely impacted patients’ lives for the good.”
– Dr. Tara Seery
PARTNERING F OR PROGRESS: Hospital Leaders on Advancing Hoag
Hoag has always had a robust enthusiasm for innovation that enhances patient care. With Hoag Innovators, Hoag now has a committed and engaged partner in advancing health care innovation, further distinguishing Hoag and directly benefiting our community. The possibilities are endless.”
Marcy Brown Hoag Senior Vice President, Chief Operations Officer, and Hoag Innovators Member
The power of Hoag Innovators is that it positions Hoag to continually and relentlessly elevate care. Because of their investment and commitment to driving innovation, Hoag is doing things other hospitals can only dream about.”
Andrew Guarni Hoag Executive Vice President and Chief Financial Officer
Hoag Innovators is one of the main reasons Hoag is able to attract a roster of renowned physicians. Physicians come to Hoag to do the best work of their lives, and the unique partnership with Hoag Innovators enables them to explore and implement cutting-edge innovations that benefit patients and our community. Our physicians and surgeons are inspired by the Hoag Innovators' visionary philanthropic model, the first of its kind in the country.”
Teresa Conk Hoag Senior Vice President and Chief Clinical Institutes Officer
BUILDING OUR BRAND, EXPANDING OUR REACH
Since our founding in 2017, the Hoag Innovators brand has become well-known and respected throughout the Hoag enterprise. As we continue to explore strategies to further our impact, an ongoing goal is to expand awareness and understanding of Hoag Innovators in communities across Orange County while encouraging potential new members to join the movement.
In 2023, Hoag Innovators and the Hoag Hospital Foundation planned a six-month advertising campaign in the Orange County Business Journal featuring members and their “why” for joining Hoag Innovators.
The campaign’s objectives were to:
• Drive awareness
• Spark curiosity
• Attract new members
• Elevate Hoag Innovators brand identity
• Create a sense of belonging, community, and relationships
Campaign Awareness
During its six-month duration, this advertising campaign dramatically increased website traffic to HoagInnovators.org, shared the dedication of Hoag Innovators members, and raised overall awareness of the program to a larger audience.
Social Media Engagement
as of 7.8.24
12,040+ users reached 1,100+ total engagement
Website Traffic as of 7.8.24
3,054+ website visitors 1,554+ users
FOR THE GREATEST GOOD
Hoag Innovators members are among Hoag Hospital Foundation's most passionate supporters, regularly conveying their enthusiasm by attending Hoag Hospital Foundation events throughout the year. Whether it’s at the Christmas Carol Ball, Hoag Summer Fest, the Circle 1000 Founders’ Celebration Brunch, or other gatherings, Hoag Hospital Foundation is grateful for Hoag Innovators’ dedication and active participation in advancing all of Hoag.
Jennifer Hofkes & Kim Snyder | H.E.R. Summit
Rick & Alexandra Taketa | Christmas Carol Ball
Tusdi Vopat & Stuart McClure | Christmas Carol Ball
Marcy Brown, Andrew Guarni, & Debbie Margolis | Hoag Heritage Society Luncheon
James Pick & Rosalyn Laudati | Boldly Hoag Salon
Pat & Jerry Jones | Patty & George Hoag Cancer Center Reopening
Dr. Demeure & Otis Healy | Patty & George Hoag Cancer Center Reopening
Diane & Jim Connelly | Boldly Hoag Salon
Sarah Booth & Vicki Booth | Circle 1000 Celebration Brunch
Hoag Innovators Advisory Board Leads with Intention
Hoag Innovators is in capable hands. In addition to Hoag Innovators co-founders Robert and Kitty Brunswick, five other individuals whose experience and expertise span industries and sectors make up the Hoag Innovators Advisory Board. Together, they provide leadership and strategic oversight over the future direction and growth of Hoag Innovators.
Over the summer, the Advisory Board convened for a four-hour planning and strategy session. The meeting also included key members of Hoag’s executive team who underscored Hoag’s commitment to partnering with Hoag Innovators as we push the boundaries of conventional philanthropy, engage new members, and catalyze transformative health care innovations.
Hoag Innovators Advisory Board:
Robert and Kitty Brunswick Co-founders
Diane Connelly
Mike Gray
Mike Roberts
Rick Taketa
George Wood
FUTURE-FOCUSED
Hoag Innovators’ commitment to catalyzing innovation across specialties and service lines has made us an integral partner in Hoag’s innovation strategy. Alongside continuing this vital work, Hoag Innovators remains focused on equipping Hoag with a sustainable platform that will advance innovation into the future, heighten our impact, and cement Hoag Innovators’ legacy. For this reason, we have set an ambitious goal of reaching a total of $50 million raised within the next five years. At the time of publishing this report, Hoag Innovators has raised more than $25 million. Achieving this goal will not only allow for our continued investment in the innovative projects of Hoag’s best and brightest clinicians today, but it will also enable significant growth of the Hoag Innovators Endowment Fund, ensuring these investments can continue in perpetuity.
We invite you to consider your role in this next evolution of Hoag Innovators. The following expanded Hoag Innovators membership levels are available to current and prospective members and offer opportunities for further involvement, additional benefits, and greater impact.
Hoag Innovators Recognition Opportunities
INNOVATORS | $250,000 - $499,999
• One vote per meeting
• Benefactor Program recognition as applicable*
• Member recognition on Innovators signage at the Newport Beach Gallery of Philanthropy and Sun Family Campus
INNOVATORS INFLUENCER | $500,000
- $999,999
• One vote per meeting
• Benefactor Program recognition as applicable*
• Two courtesy Innovator assists per year for friends or family members***
• Two complimentary tickets to:
• Hoag Classic – VIP tent access
• Hoag Summer Fest – VIP tent access
• Influencer member recognition on Innovators signage at the Newport Beach Gallery of Philanthropy and Sun Family Campus
INNOVATORS SUSTAINER | $1,000,000+**
• One vote per meeting
• Benefactor Program recognition as applicable*
• Three courtesy Innovator assists per year for friends or family members***
• Two complimentary tickets to:
• Hoag Classic – VIP tent access
• Hoag Summer Fest – VIP tent access
• Christmas Carol Ball
• Exclusive invitation to Hoag CEO Roundtable/State of the Hospital
• VIP behind-the-scenes/sneak peek experiences with Hoag physicians and leadership
• Sustainer member recognition on Innovators signage at the Newport Beach Gallery of Philanthropy and Sun Family Campus
*Benefactor Program recognition and levels are based on cumulative giving to Hoag.
**Gifts can be irrevocable estate gifts designated to Innovators or the Innovators Endowment Fund.
***Hoag Innovators at the Influencer and Sustainer levels may obtain a limited number of courtesy Innovator assists each year for friends or family members not already covered under the Benefactor Program. The courtesy Innovator assists are available during regular Hoag Hospital Foundation business hours only and can be requested through a dedicated phone number different than the Benefactor hotline. The service will provide one-time in-patient/outpatient assists and may include physician referrals or hospital visits.
For more information about Hoag Innovators, please contact Kara Kipp, executive director, principal gifts, at (949) 764-7217 or Kara.Kipp@hoag.org.